DOI:
https://doi.org/10.38017/1657463X.822Keywords:
COVID-19, SARS-CoV-2, pandemic, vaccinesAbstract
The vaccines to prevent coronavirus 2 (SARS-CoV-2), which is responsible for severe acute respiratory syndrome, have emerged as the most promising strategy to contain the pandemic. Therefore, this study is aimed at showing the progress of vaccines distributed, allocated and applied by dose for vaccination against SARS-COV-2 in the territorial entities of Colombia, between February 17 and August 5, 2021. The present study was an analytical cross-sectional study designed specially to collect information on vaccines given in Colombia. As a source of information, the national vaccination plan against COVID-19 was consulted on the website of the Ministry of Health and Social Protection. According to the data, the territorial entities with the highest percentage of doses assigned were: Bogotá (18.61), Antioquia (14.92), Valle del Cauca (8.82), and the territorial entities with the highest percentage of vaccines applied per dose were: Bogotá (18.61), Antioquia (14.92), Valle del Cauca (8.82). On the other hand, the territorial entities with the highest percentage of vaccines applied per dose were: San Andrés and Providencia (87), Valle (56.75), Atlántico (56.75), Caldas (56.72), and Vaupés (56). In conclusion, vaccination is essential during the COVID-19 pandemic to reduce infection rates and deaths. The efficacy of the vaccine is based on the formation of a long-lasting immune response and on the proportion of people who are vaccinated.
Downloads
References
Agmon-Levin, N., Paz, Z., Israelí, E. y Shoenfeld, Y. (2009). Vacunas y autoinmunidad. Nat Rev Rheumatol, 5, 648-652. https://doi.org/10.1038/nrrheum.2009.196
Anywaine, Z., Whitworth, H., Kaleebu, P., Praygod, G., Shukarev, G., Manno, D., ... y Watson-Jones, D. (2019). Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. The Journal of infectious diseases, 220(1), 46-56. https://doi.org/10.1093/infdis/jiz070
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... y Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine, 384(5), 403-416. https://doi.org/10.1056/NEJMoa2035389
Calina, D., Docea, AO., Petrakis, D., Egorov, AM., Ishmukhametov, AA., Gabibov, AG., Shtilman, MI., Kostoff, R., Carvalho, F., Vinceti, M., Spandidos, DA. y Tsatsakis, A. (2020). Towards effective COVID 19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med., 46(1), 3-16. https://doi.org/10.3892/ijmm.2020.4596
Cataño, J. y Aguirre, H. D. (2020). Vacunación del adulto en tiempos de COVID-19. Corporación de Investigaciones Biológicas, 1(2), 1-8.
CDC. (2021). Emerging SARS-CoV-2 Variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.htm
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., ... y Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine, 384(15), 1412-1423. https://doi.org/10.1056/NEJMoa2101765
Díaz, J. (2018). Análisis de los resultados del Índice Sintético de la Calidad Educativa (ISCE) 2017 de las Secretarías de Educación Certificadas de Colombia. IJERI: International Journal of Educational Research and Innovation, (10), 334-344.
Díaz, J. (2020). Perspectiva del COVID-19 en Colombia para el año 2021. Revista Repertorio de Medicina Y Cirugía, (ed. esp.) 128-133. https://doi.org/10.31260/RepertMedCir.01217372.1136
Díaz, J. (2021). Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra el SARS-COV-2 en Colombia. Revista Repertorio De Medicina Y Cirugía, (30), 41-45. https://doi.org/10.31260/RepertMedCir.01217372.1227
Doshi, P. (2020). ¿Las vacunas covid-19 salvarán vidas? Los ensayos actuales no están diseñados para informarnos. BMJ, 371, m4037. https://doi.org/10.1136/bmj.m4037
Kostoff, R. N., Briggs, M. B., Porter, A. L., Spandidos, D. A. y Tsatsakis, A. (2020b). [Comment] COVID 19 vaccine safety. International journal of molecular medicine, 46(5), 1599-1602. https://doi.org/10.3892/ijmm.2020.4733
Kostoff, R., Briggs, M. B., Porter, A. L., & Spandidos, D. A. (2020a). COVID-19 vaccine safety. International Journal of Molecular Medicine, 46(5), 1599-1602. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521561/pdf/ijmm-46-05-1599.pdf
Krause, P. R. y Gruber, M. F. (2020). Emergency use authorization of Covid vaccines—safety and efficacy follow-up considerations. New England Journal of Medicine, 383(19), e107. https://doi.org/10.1056/NEJMp2031373
Mathieu, E., Ritchie, H., Rodés-Guirao, L., Appel, C., Giattino, C., Hasell, J., Macdonald, B., Dattani, S., Beltekian, D., Ortiz-Ospina, E. y Roser, M. (2020). Coronavirus Pandemic (COVID-19). Our World in Data. https://ourworldindata.org/covid-vaccinations https://ourworldindata.org/covid-vaccinations
Mathioudakis, AG., Ghrew, M., Ustianowski, A., Ahmad, S., Borrow, R., Papavasileiou, LP., Petrakis, D. y Bakerly, ND. (2021). Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel), 11(3), 249. https://doi.org/10.3390/life11030249
Ministerio de Salud y Protección Social de Colombia. (s.f.). Plan de vacunación nacional contra COVID-19. https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... y Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577
Puthumana, J., Egilman, A. C., Zhang, A. D., Schwartz, J. L. y Ross, J. S. (2021). Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration. JAMA Internal Medicine, 181(4), 559-560. https://doi.org/10.1001/jamainternmed.2020.7472
Ramírez, J. A. (2021). Vacunas para COVID-19. Respirar, 13(1), 03-06. https://respirar.alatorax.org/index.php/respirar/article/view/62
Spinola, S. M., Zimet, G. D., Ott, M. A. y Katz, B. P. (2020). Human challenge studies are unlikely to accelerate coronavirus vaccine licensure due to ethical and practical issues. The Journal of infectious diseases, 222(9), 1572-1574. https://doi.org/10.1093/infdis/jiaa457
World Health Organization. (2023). Organización Mundial de la Salud. Vacunas para COVID-19. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
World Health Organization. (s.f.). COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Cultura científica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
